Glucagon-like Peptide―1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
- Author
- GALLWITZ, Baptist1
[1] Medizinische Klinik IV, Eberhard-Karls University, Tubingen, Germany - Source
Drugs (Basel). 2011, Vol 71, Num 13, pp 1675-1688, 14 p ; ref : 99 ref
- CODEN
- DRUGAY
- ISSN
- 0012-6667
- Scientific domain
- Pharmacology drugs
- Publisher
- Adis International, Auckland
- Publication country
- New Zealand
- Document type
- Article
- Language
- English
- Keyword (fr)
- Analogue Article synthèse Diabète de type 2 Efficacité traitement Forme commerciale Homme Peptide GLP1 Physiologie Incrétine Endocrinopathie Hormone gastrointestinale Maladie métabolique
- Keyword (en)
- Analog Review Type 2 diabetes Treatment efficiency Commercial form Human Glucagon like peptide 1 Physiology Incretin Endocrinopathy Gastrointestinal hormone Metabolic diseases
- Keyword (es)
- Análogo Artículo síntesis Diabetes de tipo 2 Eficacia tratamiento Forma comercial Hombre Péptido GLP1 Fisiología Incretina Endocrinopatía Hormona gastrointestinal Metabolismo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02O Hormones. Endocrine system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Discipline
- Endocrinopathies Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24592442
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2165/11592810-000000000-00000 
https://dx.doi.org/10.2165/11592810-000000000-00000
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1675\";s:8:\"\u0000*\u0000epage\";s:4:\"1688\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GALLWITZ\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Baptist\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1675\";s:8:\"\u0000*\u0000epage\";s:4:\"1688\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GALLWITZ\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Baptist\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1675\";s:8:\"\u0000*\u0000epage\";s:4:\"1688\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GALLWITZ\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Baptist\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1675\";s:8:\"\u0000*\u0000epage\";s:4:\"1688\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GALLWITZ\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Baptist\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/11592810-000000000-00000\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1675\";s:8:\"\u0000*\u0000epage\";s:4:\"1688\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GALLWITZ\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Baptist\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:93:\"Glucagon-like Peptide\u20151 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
